Tesamorelin
Also known as: Egrifta, Egrifta SV, GHRH(1-44)-NH2 analogue, GHRH(1‑44) analog, hGRF(trans-3-hexenoic acid), Tesamorelin acetate, TH9507
Source Tesamorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Tesamorelin is a synthetic analogue of growth‑hormone‑releasing hormone (GHRH) that is approved as a prescription drug for the treatment of abdominal fat accumulation in people living with HIV. It is administered by subcutaneous injection and works by stimulating endogenous growth‑hormone release, which in turn raises circulating insulin‑like growth factor‑1 (IGF‑1). While it has demonstrated metabolic benefits in HIV‑related lipodystrophy, current orthopaedic and sports‑medicine literature reports no clinical evidence supporting its use for musculoskeletal injury or performance enhancement.
Mechanism of Action
Tesamorelin binds to the GHRH receptor on pituitary somatotrophs, mimicking the native hormone and amplifying pulsatile growth‑hormone secretion. The resulting increase in circulating GH elevates hepatic IGF‑1 production, activating downstream PI3K/Akt and MAPK pathways that regulate protein synthesis, cell growth, and tissue remodeling. Through IGF‑1 signaling, tesamorelin can influence satellite‑cell activity and adipose‑tissue metabolism, which underlies its approved effect on visceral fat reduction.
What the Research Shows
Two recent narrative reviews of injectable peptide therapies for orthopaedic and sports‑medicine applications note that tesamorelin, although FDA‑approved for HIV‑associated lipodystrophy, lacks any supporting orthopaedic evidence. A 2024 randomized, double‑blind trial in 61 HIV‑positive participants on integrase‑inhibitor regimens compared tesamorelin 2 mg daily with placebo for 12 months. In the 31 completers, tesamorelin produced statistically significant reductions in visceral fat, hepatic fat fraction, and trunk‑to‑appendicular fat ratio, with a safety profile comparable to placebo. No trials have examined its effect on musculoskeletal healing, performance, or injury recovery.
Reported Benefits
In the HIV population, tesamorelin has been shown to reduce abdominal (visceral) fat, lower hepatic fat content, and improve body‑fat distribution without worsening glycaemic control. These metabolic benefits are documented in a randomized controlled trial and support its approved indication for HIV‑associated lipodystrophy. Outside this context, no clinical benefit for orthopaedic or athletic outcomes has been demonstrated.
Limitations of the Evidence
Evidence for tesamorelin outside HIV‑related metabolic disease is absent; orthopaedic and sports‑medicine reviews report a complete lack of human trials for tissue repair or performance. The available efficacy data stem from a single modest‑size trial (31 completers) focused on body composition, limiting generalizability. Potential benefits for muscle or bone healing remain speculative, based only on mechanistic reasoning rather than empirical data.
Safety Considerations
The 2024 HIV trial reported that tesamorelin was well tolerated, with adverse‑event rates similar to placebo, including comparable incidences of hyperglycaemia. No serious safety signals emerged in the reviewed orthopaedic literature, but the absence of systematic safety data for musculoskeletal use means that risks in that setting are unknown. Routine monitoring of glucose and metabolic parameters is advisable when used for its approved indication.
How It Is Administered
Tesamorelin is administered by subcutaneous injection. In the published randomized trial, the regimen was a daily 2 mg dose given once each day. The drug is supplied as a sterile solution for injection and is intended for self‑administration under medical supervision in the approved indication.
Routes of Administration
Goals & Uses
- Improvement of lipid profileCardiovascular / MetabolicModerate
- Reduction of non-alcoholic fatty liver disease (NAFLD/NASH)Hepatic / MetabolicLow
- Reduce visceral adipose tissue in HIV‑associated lipodystrophyMetabolicHigh
- General anti-aging / GH optimizationWellness / Off LabelLow
- Improve lipid profileCardiovascularModerate
- Lean body mass preservationBody CompositionModerate
- Reduction of HIV-associated lipodystrophy (visceral adiposity)Metabolic / Body CompositionHigh
- Cognitive function improvement in older adultsNeurocognitiveModerate
Contraindications
- Active malignancyOncologyModerateUse caution or avoid depending on agent and context
- Known hypersensitivity to tesamorelin or excipientsAllergyHigh
- Disruption of hypothalamic-pituitary axis (e.g., pituitary tumor, head trauma, cranial irradiation)EndocrineHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Diabetic retinopathyOphthalmologyModerate
- Hypersensitivity to tesamorelin or mannitolAllergic / ImmunologicHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Joint pain (arthralgia)MusculoskeletalCommon
- Fluid retention / peripheral edemaCardiovascularCommon
- Carpal tunnel syndromeMusculoskeletalUncommon
- Hypersensitivity reactions (rash, urticaria)ImmunologicUncommon
- Hyperglycemia / glucose intoleranceMetabolic / EndocrineUncommon
- Arthralgia / myalgiaMusculoskeletalCommon
- Injection site reactions (erythema, pruritus, pain, induration)Dermatologic / LocalCommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsLow
- Glucocorticoids (systemic)Moderate
- Cytochrome P450-metabolized drugs (e.g., cortisol, sex steroids, anticonvulsants)Low
- Somatostatin analogues (octreotide, lanreotide)High
- Antidiabetic medications (insulin, oral hypoglycemics)Moderate
Population Constraints
- Pediatric patientsAgeAbsolute
- Patients with uncontrolled diabetesMetabolicRelative
- Elderly patients (>65 years)AgeRelative
- Patients with diabetes mellitusMetabolicRelative
- Pregnant womenReproductiveAbsolute
- Patients with renal or hepatic impairmentOrgan FunctionRelative
Regulatory Status
- European UnionUnapprovedNot authorized; available only in clinical trials.
- United StatesApprovedApproved: HIV‑associated lipodystrophy (excess abdominal fat)Approved under brand name Egrifta; prescription only.
- United KingdomUnapprovedNo marketing authorization; investigational use permitted.
FDA‑approved in 2003 (Egrifta) for HIV‑associated lipodystrophy; not approved in the EU.
Evidence & Sources
- Journal ArticleModerateRahman OF, Lee SJ, Seeds WA2026-01-01T00:00:00.000000Z
- Journal ArticleModerateMayfield CK, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateRusso SC, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateMendias CL, Awan TM2026-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is tesamorelin officially approved to treat?
Tesamorelin is FDA‑approved for the reduction of excess abdominal (visceral) fat in adults living with HIV who have lipodystrophy, based on its ability to increase growth‑hormone and IGF‑1 levels.
Can tesamorelin help heal sports‑related injuries or improve performance?
Current peer‑reviewed literature provides no clinical evidence that tesamorelin benefits musculoskeletal injury repair or athletic performance. Its use for those purposes remains experimental and unsupported.
What are the main side effects reported with tesamorelin?
In a controlled trial, tesamorelin showed a safety profile similar to placebo, with hyperglycaemia occurring at comparable rates. No serious adverse events were reported, but long‑term safety outside the HIV indication has not been established.
How is tesamorelin given and how often?
The drug is supplied as a sterile solution for subcutaneous injection. In the published study, participants received a single daily injection of 2 mg, administered under medical guidance.
Is tesamorelin available without a prescription for fitness purposes?
Tesamorelin is a prescription‑only medication approved for a specific medical indication. It is not legally marketed for fitness or injury‑recovery uses, and obtaining it without a prescription would be off‑label and unregulated.
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth‑hormone‑releasing hormone (GHRH) that is approved as a prescription drug for the treatment of abdominal fat accumulation in people living with HIV. It is administered by subcutaneous injection and works by stimulating endogenous growth‑hormone release, which in turn raises circulating insulin‑like growth factor‑1 (IGF‑1). While it has demonstrated metabolic benefits in HIV‑related lipodystrophy, current orthopaedic and sports‑medicine literature reports no clinical evidence supporting its use for musculoskeletal injury or performance enhancement.
What is Tesamorelin used for?
Tesamorelin is educationally associated with: Improvement of lipid profile, Reduction of non-alcoholic fatty liver disease (NAFLD/NASH), Reduce visceral adipose tissue in HIV‑associated lipodystrophy, General anti-aging / GH optimization, Improve lipid profile, Lean body mass preservation, Reduction of HIV-associated lipodystrophy (visceral adiposity), Cognitive function improvement in older adults. Educational only — not medical advice.
How is Tesamorelin administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Tesamorelin?
Reported adverse effects include: Edema, Hyperglycemia, Joint pain (arthralgia), Fluid retention / peripheral edema, Carpal tunnel syndrome, Hypersensitivity reactions (rash, urticaria), Hyperglycemia / glucose intolerance, Arthralgia / myalgia, Injection site reactions (erythema, pruritus, pain, induration), Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Tesamorelin?
Recorded contraindications: Active malignancy, Known hypersensitivity to tesamorelin or excipients, Disruption of hypothalamic-pituitary axis (e.g., pituitary tumor, head trauma, cranial irradiation), Pregnancy, Diabetic retinopathy, Hypersensitivity to tesamorelin or mannitol. Consult a qualified clinician before use.